1.
Gestational trophoblastic neoplasia: one size does not fit all – Authors' reply
by Braga, Antonio
The lancet oncology, 2021, Vol.22 (10), p.e421-e421
2.
Correction to Lancet Oncol 2019; 20: 1506–517
The lancet oncology, 2019, Vol.20 (11), p.e613-e613
3.
Omission of doxorubicin from the treatment of stage II–III, intermediate-risk Wilms' tumour (SIOP WT 2001): an open-label, non-inferiority, randomised controlled trial
by Pritchard-Jones, Kathy, Prof
The Lancet (British edition), 2015, Vol.386 (9999), p.1156-1164
4.
super(18)F-FDG PET/CT impact on testicular tumours clinical management
by Ambrosini, Valentina
European journal of nuclear medicine and molecular imaging, 2014, Vol.41 (4), p.668-673
5.
Accurate assessment of long-term nephrotoxicity after peptide receptor radionuclide therapy with super(177)Lu-octreotate
by Sabet, Amir
European journal of nuclear medicine and molecular imaging, 2014, Vol.41 (3), p.505-510
7.
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial
by Iwata, Hiroji
The lancet oncology, 2017, Vol.18 (12), p.1688-1700
8.
Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, c...
by Gronchi, Alessandro, Dr
The lancet oncology, 2017, Vol.18 (6), p.812-822
9.
Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a ran...
by Gay, Francesca, MD
The lancet oncology, 2015, Vol.16 (16), p.1617-1629
10.
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
by Locke, Frederick L
The lancet oncology, 2019, Vol.20 (1), p.31-42
11.
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial
by Baselga, José, Dr
The Lancet (British edition), 2012, Vol.379 (9816), p.633-640
12.
Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final result...
by Chiappella, Annalisa
The lancet oncology, 2017, Vol.18 (8), p.1076-1088
13.
Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase...
by Neoptolemos, John P, Prof
The Lancet (British edition), 2017, Vol.389 (10073), p.1011-1024
14.
Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3–pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, rand...
by Sternberg, Cora N, Dr
The lancet oncology, 2015, Vol.16 (1), p.76-86
15.
Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phas...
by Moreno, Carol
The lancet oncology, 2019, Vol.20 (1), p.43-56
16.
A new standard of care for patients with high-risk rhabdomyosarcoma? – Authors' reply
by Bisogno, Gianni
The lancet oncology, 2020, Vol.21 (1), p.e3-e3
17.
A systematic review and meta-analysis of the randomized controlled trials on adjuvant intraperitoneal chemotherapy for resectable gastric cancer
by Yan, Tristan D
Annals of surgical oncology, 2007, Vol.14 (10), p.2702-2713
18.
Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trial
by Del Mastro, Lucia, Dr
The Lancet (British edition), 2015, Vol.385 (9980), p.1863-1872
19.
Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-infe...
by Yamada, Yasuhide, Dr
The lancet oncology, 2013, Vol.14 (13), p.1278-1286
20.
Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicent...
by Gianni, Luca, Dr
The lancet oncology, 2012, Vol.13 (1), p.25-32
